Medical company Summit Medical Group said on Monday that the Department of Ear Nose & Throat/Allergy conducted a clinical trial that led the US Food & Drug Administration (FDA) to approve the nasal spay XHANCE (fluticasone proprionate) for the treatment of nasal polyps in patients 18 years of age or older.

The XHANCE clinical trial is reportedly part of the company's larger initiative to advance medicine.

Currently, the company is involved in 31 active clinical trials, which are critical to the development of new therapies, including finding innovative treatments for cancer, rheumatoid arthritis, type 2 diabetes as well as allergies.

In the US, about 10 million people suffer from the benign growths that block the nasal passages and cause congestion, pain and pressure, sinus infections and difficulty breathing.